Seek Returns logo

ASND vs. GH: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at ASND and GH, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

ASND dominates in value with a market cap of 9.55 billion USD, eclipsing GH’s 4.60 billion USD by roughly 2.08×.

GH carries a higher beta at 1.49, indicating it’s more sensitive to market moves, while ASND remains steadier at 0.40.

ASND trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while GH remains a standard domestic listing.

SymbolASNDGH
Company NameAscendis Pharma A/SGuardant Health, Inc.
CountryDKUS
SectorHealthcareHealthcare
IndustryBiotechnologyMedical - Diagnostics & Research
CEOMr. Jan Moller MikkelsenDr. Helmy Eltoukhy Ph.D.
Price158.1 USD37.09 USD
Market Cap9.55 billion USD4.60 billion USD
Beta0.401.49
ExchangeNASDAQNASDAQ
IPO DateJanuary 28, 2015October 4, 2018
ADRYesNo

Performance Comparison

This chart compares the performance of ASND and GH over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of ASND and GH based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • Neither ASND nor GH turned a profit—both carry negative P/E ratios of -24.55 and -11.03, underscoring continued losses that pressure their valuations.
  • ASND posts a negative forward PEG of -2.23, hinting at anticipated earnings decline, whereas GH at 0.46 has projections for stable or growing earnings.
  • Book value is underwater for both ASND (-44.19) and GH (-18.32), meaning liabilities exceed assets—signaling a critical solvency risk for both companies.
  • ASND and GH both consumed more free cash flow than they generated last year—P/FCF of -27.43 and -15.07, respectively—highlighting persistent liquidity pressure.
SymbolASNDGH
Price-to-Earnings Ratio (P/E, TTM)-24.55-11.03
Forward PEG Ratio (TTM)-2.230.46
Price-to-Sales Ratio (P/S, TTM)22.885.94
Price-to-Book Ratio (P/B, TTM)-44.19-18.32
Price-to-Free Cash Flow Ratio (P/FCF, TTM)-27.43-15.07
EV-to-EBITDA (TTM)-35.74-13.08
EV-to-Sales (TTM)23.786.72
EV-to-Free Cash Flow (TTM)-28.50-17.07

Dividend Comparison

Neither ASND nor GH currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.

SymbolASNDGH
Dividend Yield (TTM)0.00%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of ASND and GH, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • ASND’s quick ratio of 0.71 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas GH at 3.76 maintains a comfortable buffer of liquid assets.
  • Both ASND (debt-to-equity ratio -4.46) and GH (-5.21) exhibit negative shareholder equity—assets fall short of liabilities—signaling serious balance-sheet stress.
  • GH carries a debt-to-assets ratio of 0.97, suggesting substantial asset funding via debt, while ASND at 0.80 opts for a more conservative financing structure.
  • Both ASND and GH report negative interest coverage ratios (-3.72, -166.83), meaning EBIT itself is negative—neither can cover interest, a critical solvency warning.
SymbolASNDGH
Current Ratio (TTM)1.044.11
Quick Ratio (TTM)0.713.76
Debt-to-Equity Ratio (TTM)-4.46-5.21
Debt-to-Assets Ratio (TTM)0.800.97
Interest Coverage Ratio (TTM)-3.72-166.83